ArticleEuropean journal of nuclear medicine and molecular imaging2018
18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start.
Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- The value ofEuropean journal of nuclear medicine and molecular imaging · 2021Pooled it
- Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.Melanoma research · 2019Pooled it
- Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.Journal for immunotherapy of cancer · 2019Trial
- The role of interimEuropean journal of nuclear medicine and molecular imaging · 2018Trial
- FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- The radiological appearances of lung cancer treated with immunotherapy.The British journal of radiology · 2023Review
- Development of a Hybrid-Imaging-Based Prognostic Index for Metastasized-Melanoma Patients in Whole-Body 18F-FDG PET/CT and PET/MRI Data.Diagnostics (Basel, Switzerland) · 2022Article
- Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment.International journal of molecular sciences · 2022Review
- CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [Journal of clinical medicine · 2021Review
- Precision Nuclear Medicine: The Evolving Role of PET in Melanoma.Radiologic clinics of North America · 2021Review
- Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy.Cancers · 2021Review
- Value ofCancer imaging : the official publication of the International Cancer Imaging Society · 2021Review
- Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model.Therapeutic advances in medical oncology · 2021Review
- Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma.Frontiers in oncology · 2021Article
- FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls.Seminars in nuclear medicine · 2020Review
- Is there a link between very early changes of primary and secondary lymphoid organs inJournal for immunotherapy of cancer · 2020Article
- Relationship Between Tumor Immune Markers and Fluorine-18-α-Methyltyrosine ([Molecular imaging and biology · 2020Article
- Predictive value of positron emission tomography for the prognosis of immune checkpoint inhibitors (ICIs) in malignant tumors.Cancer immunology, immunotherapy : CII · 2020Article
- Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications.Cancers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
purposeThe aim of the study was to evaluate if 18F-FDG-PET has the potential to detect complete responders to PD1-therapy in patients with unresectable metastasized melanoma two weeks after therapy initiation.
methodsBetween September 2014 and May 2016, ten patients (four females; 65 ± 12 y) received a whole-body 18F-FDG-PET/MRI examination at three time points: Before therapy start (t
resultsThree patients with partial metabolic response in PET at t
conclusionOur study indicates that whole-body 18F-FDG-PET might be able to reliably identify complete responders to PD1-therapy as early as two weeks after therapy initiation in stage IV melanoma patients. This might help to shorten therapy regimes and avoid unnecessary side effects in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.